A wave of new data is putting trastuzumab‑deruxtecan (T‑DXd) in the spotlight as a game‑changing therapy for several HER‑2 driven cancers. In a Chinese trial for HER‑2‑mutant non‑small cell lung cancer, researchers identified 5.4 mg/kg every three weeks as the sweet spot—offering strong tumor shrinkage while keeping side‑effects manageable. At the 2023 ESMO Asia meeting, the DESTINY‑Gastric06 study showed impressive response rates in Chinese patients with advanced HER‑2‑positive gastric cancer, paving the way for imminent regulatory approval. A real‑world retrospective analysis confirmed that heavily pre‑treated breast‑cancer patients—both HER‑2‑positive and HER‑2‑low—still benefit from T‑DXd with tolerable toxicity. The TUXEDO‑1 trial demonstrated that the drug can cross the blood‑brain barrier, controlling brain metastases and extending progression‑free survival. In the DESTINY‑Breast02 phase‑III study, T‑DXd outperformed its predecessor T‑DM1 after disease progression, and long‑term data from a separate trial showed superior overall survival, response rates, and durability. With six HER‑2‑targeted antibody‑drug conjugates now competing, T‑DXd’s consistent efficacy across lung, gastric, and breast cancers positions it as a leading contender in the next wave of oncology treatments.
Read moreA home‑grown team has unveiled “Beibrain One,” the world’s first semi‑invasive brain‑computer system that can read hundreds of neural signals at once. Fully implantable and ready for real‑world use, it has already helped five patients with spinal‑cord injuries, strokes or ALS regain movement with assistive devices and even restore speech for those with aphasia. At Dalian University, researchers built a rehabilitation interface that translates a patient’s intention into limb feedback, re‑creating the brain‑body link for nerve‑damage recovery. Meanwhile, a new autism‑diagnosis aid, certified as a Class II medical device, correctly identifies the condition over 90 % of the time and supports effective neurological interventions. Traditional brain‑stimulators work in a fixed, “open‑loop” mode. New brain‑inspired chips, however, monitor brain activity in real time and adjust stimulation on the fly, offering personalized treatment for Parkinson’s, epilepsy and other disorders. A memristor‑based system from Peking University now decodes muscle signals for smarter prosthetic control. Wearable health monitors are also getting a boost: ultra‑low‑power neuromorphic chips can run for months on a tiny button battery, opening the door to continuous chronic‑disease tracking. The global market for these spiking‑neural‑network chips is projected to jump from $35 million in 2025 to $661 million by 2031, with China at the forefront of research, patents and industrial rollout. While challenges remain in core hardware and software tools, China’s massive market and strong policy support give it a clear advantage to lead the next wave of brain‑inspired technology.
Read moreFor years doctors believed atrophic gastritis – a thinning of the stomach lining that can lead to cancer – was permanent. Recent studies have turned that idea on its head. Large, multi‑center trials show that with the right combination of medicines and long‑term care, many patients can see real healing of the stomach lining and even a partial reversal of intestinal metaplasia, a precancerous change. The most talked‑about breakthrough is a Chinese herbal formula (Qilian Xiaopi/WW‑1) tested in 13 top hospitals on 468 patients. After 6‑12 months of treatment, researchers saw clear signs that the lining’s thickness improved and harmful cell changes receded. The herb appears to calm chronic inflammation by shifting immune cells from a damaging to a healing mode. Other promising options include a lamb‑stomach extract rich in vitamin B12, which reversed intestinal metaplasia in about half of the participants, especially when paired with the drug teprenone. Even the diabetes pill metformin showed a 53 % reversal rate in non‑diabetic patients, working through a cellular pathway that reduces inflammation and promotes healthy cell recycling. New protective agents like rebamipide, and classic combos of teprenone with folic acid, also delivered notable improvements when used for a year or more. On the research front, single‑cell sequencing has uncovered weakened stomach‑cell defenses and a type of cell death called ferroptosis, pointing to fresh drug targets. Low vitamin D levels were linked to faster disease progression, suggesting supplementation could help, while studies of the stomach’s microbiome hint that restoring a balanced bacterial community may be another therapeutic angle. Together, these findings give patients and doctors a realistic roadmap: eradicate H. pylori, follow a tailored medication plan, and monitor progress with regular endoscopies. The era of “irreversible” atrophic gastritis may be ending.
Read more